Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
W. Michael Scheld*
Table 5
Risk factors for infection or colonization with fluoroquinolone-resistant Streptococcus pneumoniaea
| Factor | Case patients (n=27) | Control patients (n=54) | Odds ratio (95% CI) | p value | |
|---|---|---|---|---|---|
| Age (yr)b |
72.5
(62.3–78.3) |
75 (70–85) |
– |
0.01 |
|
| Nursing home residence |
14 (52%) |
7 (13%) |
7.2 (2.4 to 21.6) |
< /> |
|
| COPD |
17 (63%)c |
12 (22%) |
5.9 (2.2 to 16.3) |
0.001 |
|
| Nosocomial
origin |
18 (66%) |
14 (26%) |
5.7 (2.1 to 15.6) |
0.001 |
|
| Interval from day of admission to isolation of LRSP (days)b |
7 (1–20) |
1 (1–3) |
- |
< /> |
|
| No. of prior
admissionsb |
4 (2–7) |
1 (0–3) |
- |
< /> |
|
| Recent hospitalization |
16 (59%) |
13 (24%) |
4.6 (1.7 to 12.3) |
0.003 |
|
| Multiple hospitalization |
15 (56%) |
12 (22%) |
4.4 (1.6 to 11.8) |
0.004 |
|
| Previous exposure to antimicrobial agentsd |
|||||
| Fluoroquinolones |
8 (30%)/14 (52%) |
0 (0%)/5 (9%) |
―/10.6 (3.2 to 34.7) |
<0.001>< /> |
|
| β-lactam antibiotics | 24 (89%)/25 (93%) | 20 (37%)/32 (59%): | 14.7 (3.9 to 55.4)/8.6 (1.8 to 40) | <0.001> | |
aCI, confidence interval; COPD, chronic obstructive pulmonary disease; LRSP, levofloxacin-resistant S. pneumoniae (73).
bMedian (interquartile range).
cColonization in 3 patients.
dExposure to antimicrobial therapy during the 6 weeks prior to hospitalization/12 months before hospitalization.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.